N-HETEROCYCLYL PIPERIDINES, PIPERAZINES AND HOMOPIPERAZINES

New cyclic compounds having a cycloalkylene chain, a process for their preparation and pharmaceutical compositions containing them

ANXIOLYTIC-R-N-(1-AZABICYCLO(2.2.2)OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES

N-ARYL OXAZOLIDINONE AND PYRROLIDINONES.

N-ARYL OXAZOLIDINONE, [...], SUBSTITUTED PYRROLIDINONES, PYRROLIDINES AND THE THIAZOLIDINONES, PROCESSES FOR THEIR PREPARATION, MEDICAMENTS CONTAINING THEM AND.

Compounds derived from aryl carbamates, preparation thereof and uses of same

Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them

OXAZOLIDINONE-2 DERIVATIVES

New O-arylmethyl-N-(thio)acylhydroxylamines, process for preparing them and pharmaceutical compositions containing them

Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them

New arylalkyl (thio)amides, process for preparing them and pharmaceutical compositions containing them

5-AMINOETHYLOXAZOLIDIN-2-ONE DERIVATIVES

ANXIOLYTIC-R-N-(1-AZABICYCLO(2.2.2)OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES

Electron tube control grid

5-HYDROXYETHYL DERIVATIVES OF OXAZOLIDINONE-2, THEIR PREPARATION AND THEIR THERAPEUTIC USES

COMPOUNDS DERIVED FROM ARYL CARBAMATES, PREPARATION THEREOF AND USES OF SAME

N-HETEROCYCLYL PIPERIDINES, PIPERAZINES AND HOMOPIPERAZINES

3-AMINO QUINUCLIDINE DERIVATIVES

MEMORY ENHANCING-R-N-(1-AZABICYCLO(2.2.2)OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES

Novel tricyclic amides, processes for their preparation and the pharmaceutical compositions which contain them

Use of 4-amino-5-chloro-2-methoxybenzoic esters as 5-ht4 agonists

N-ARYL OXAZOLIDINONES AND N-ARYL PYRROLIDONES

PARA QUINONE OR ORTHO QUINONE DERIVATIVES

Novel tricyclic compounds, preparation method and pharmaceutical compositions containing same

Novel tricyclic amides, processes for their preparation and the pharmaceutical compositions which contain them

Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them

ENANTIOMERS OF ABSOLUTE CONFIGURATIONS OF AMIDE DERIVATIVES OF 3-AMINOQUINUCLIDINE, THE PROCESS FOR PREPARING THEM AND THEIR APPLICATION IN THERAPY

OPTICALLY-ACTIVE DERIVATIVES OF N-ARYLATED OXAZOLIDINE-2- ONES

5H-FURANONE-2 AND 3H-DIHYDROFURANONE-2 DERIVATIVES

ENANTIOMERS OF ABSOLUTE CONFIGURATIONS OF AMIDE DERIVATIVES OF 3-AMINOQUINUCLIDINE, THE PROCESS FOR PREPARING THEM AND THEIR APPLICATION IN THERAPY

Novel tricyclic compounds, preparation method and pharmaceutical compositions containing same

5-SUBSTITUTED TETRAZOLE DERIVATIVES

New cyclic compounds having a cycloalkylene chain, a process for their preparation and pharmaceutical compositions containing them

Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them

BETA-AMINO-3-NONTROPHANE DERIVATIVES

New O-arylmethyl-N-(thio)acylhydroxylamines, process for preparing them and pharmaceutical compositions containing them

DERIVES 5-AMINOETHYLES DE L'OXAZOLIDINONE-2, LEUR PROCEDE DE PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

MELANGE DES 4 STEREOISOMERES DE FORMULE I CI-DESSOUS, CHACUN DES COUPLES DE DIASTEREOISOMERES RACEMIQUES CORRESPONDANTS ET CHACUN DES ENANTIOMERES CORRESPONDANT A CHAQUE COUPLE, C'EST-A-DIRE CHACUN DESDITS STEREOISOMERES : (CF DESSIN DANS BOPI) DANS LAQUELLE R REPRESENTE : - UN ATOME D'HYDROGENE, - UN GROUPE ALKOXY COMPORTANT DE 1 A 4 ATOMES DE CARBONE, - UN GROUPE TRIFLUOROMETHYLE, OU - UN OU DEUX ATOMES D'HALOGENE;ET LE COUPLE R, R PREND L'UNE DES SIGNIFICATIONS SUIVANTES : (H, H), (H ALKYLE EN C-C), (ALKYLE EN C-C, ALKYLE EN C-C),AINSI QUE LEURS SELS D'ADDITION D'ACIDE ORGANIQUE ET MINERAL.

Aryl carbamate derivatives, preparation and use thereof

N-ARYL OXAZOLIDINONES AND N-ARYL PYRROLIDONES

ENANTIOMERES DE CONFIGURATION ABSOLUE S DE DERIVES AMIDE DE L'AMINO-3 QUINUCLIDINE, LEUR PROCEDE DE PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE

ENANTIOMERE DE CONFIGURATION ABSOLUE S DE FORMULE : (CF DESSIN DANS BOPI) OU X O OU S. AR REPRESENTE UN NOYAU PHENYLE SUBSTITUE PAR UN, DEUX OU TROIS GROUPES ALKOXY EN C-C; UN NOYAU PHENYLE SUBSTITUE EN POSITION 2 PAR UN GROUPE CH ET EN POSITION 5 PAR UN ATOME D'HALOGENE OU UN GROUPE ALKYLCARBONYLE INFERIEUR; UN NOYAU PHENYLE SUBSTITUE EN POSITION 2 PAR OCH, EN POSITION 4 PAR NH OU ALKYLCARBONYLE -NH- ET EN POSITION 5 PAR UN HALOGENE; UN GROUPE (FLUORO-3 METHOXY-2) PHENYLE; UN GROUPE PYRIMIDYNYLE-5 SUBSTITUE EN POSITION 2 PAR NH ET EN POSITION 4 PAR ALKOXY OU PHENYLOXY. CES COMPOSES SONT UTILES EN TANT QUE MEDICAMENTS A ACTIVITE GASTROCINETIQUE ET ANTIEMETIQUE.

ANTISCHIZOPHRENIC-S-N-(1-AZABICYCLO(2.2.2)OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES

SELECTIVE OXIDISING SYSTEM

Novel 3,5-dimethylpiperidin-1-ylalkyl esters

I-SPIRO ISOBENZOFURANIC AND I-SPIRO ISOBENZOTHIOPHENIC DERIVATIVES

ANTI-DEPRESSANT N-ARYL-OXAZOLIDINONES

OXAZOLIDINONE-2 DERIVATIVES

3-AMINO QUINUCLIDINE DERIVATIVES

New arylalkyl (thio)amides, process for preparing them and pharmaceutical compositions containing them

ANTISCHIZOPHRENIC-S-N-(1-AZABICYCLO(2.2.2)OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES

MEMORY ENHANCING-R-N-(1-AZABICYCLO(2.2.2)OCT-3-YL) BENZAMIDES AND THIOBENZAMIDES

Grid electron tube with improved performance characteristics

Grid electron tube with improved performance characteristics

FAST DISSOCIATING DOPAMINE 2 RECEPTOR ANTAGONISTS

The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects. 2. A compound according to wherein Ris trifluoromethyl; and R claim 1 , Rand Rare hydrogen.3. A compound according to wherein Ris hydrogen or methyl.4. A compound according to wherein Ris 4-fluorophenyl or 3 claim 1 ,4-difluorophenyl.5. A compound according to wherein the compound is N-[1-(4-fluorobenzyl)piperidin-4-yl]-6-(trifluoromethyl)pyridazin-3-amine.6. A compound according to wherein the compound is N-[1-(3 claim 1 ,4-difluorobenzyl)piperidin-4-yl]-6-(trifluoromethyl)pyridazin-3-amine.7. A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in .8. A compound as defined in for use as a medicine.9. A compound as defined in for use as an antipsychotic.10. A compound as defined in for use as a medicine in the treatment or prevention of schizophrenia claim 8 , schizophreniform disorder claim 8 , schizoaffective disorder claim 8 , delusional disorder claim 8 , brief psychotic disorder claim 8 , shared psychotic disorder claim 8 , psychotic disorder due to a general medical condition claim 8 , substance-induced psychotic disorder claim 8 , psychotic disorder not otherwise specified; psychosis associated with dementia; major depressive disorder claim 8 , dysthymic disorder claim 8 , premenstrual dysphoric disorder claim 8 , depressive disorder not otherwise specified claim 8 , Bipolar I disorder claim 8 , bipolar II disorder claim 8 , cyclothymic disorder claim 8 , bipolar disorder not otherwise specified claim 8 , mood disorder due to a general medical condition claim 8 , substance-induced mood disorder claim 8 , ...

Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists

The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.

Fast-dissociating dopamine 2 receptor antagonists

The present invention relates to 4-aryl-6-piperazin-1-yl-3-substituted-pyridazines that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.

COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO-[4,3-A]]QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN THE TREATMENT OF NEUROLOGICAL OF METABOLIC DISORDERS

The present invention relates to combinations of phosphodiesterase 2 (PDE2) inhibitors with inhibitors of phosphodiesterase 10 (PDE10). In particular, the invention relates to combinations of 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives which have been found to inhibit phosphodiesterase 2 (PDE2), with inhibitors of phosphodiesterase 10 (PDE10). Particular PDE10 inhibitors are selected from the group of MP-10, PQ-10, TP-10, papaverine, and the compounds disclosed in WO 2011/051324 and in WO 2011/110545. The invention is also directed to pharmaceutical compositions comprising such combinations, to processes for preparing such compositions, to the use of PDE2 inhibitors, in particular of 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives for the potentiation of said PDE10 inhibitors, and to the use of said PDE10 inhibitors for the potentiation of the effect of said PDE2 inhibitors, in particular, 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives, and to the use of such combinations and compositions for the prevention and treatment of disorders in which PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases. 5. The composition according to , wherein the one or more PDE10 inhibitors are selected from the group of MP-10 , PQ-10 , TP-10 , papaverine , a compound of Formula (II) as defined in , and a compound of Formula (III) as defined in .7. The composition according to claim 6 , comprising a carrier and as a first active ingredient a PDE2 inhibitor or a pharmaceutically acceptable salt or a solvate thereof claim 6 , and as second active ingredient one or more PDE10 inhibitor(s) claim 6 , each in an amount producing a therapeutic effect in patients suffering from neurological or psychiatric disorders claim 6 , or endocrinological or metabolic diseases.13. A process for making a pharmaceutical composition as defined in claim 5 ,comprising intimately admixing said ...

N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones

N-aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones are disclosed. These compounds possess antidepressant activity.

Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl-[1,2,4]triazolo-[4,3-A]]quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological of metabolic disorders

The present invention relates to combinations of phosphodiesterase 2 (PDE2) inhibitors with inhibitors of phosphodiesterase 10 (PDE10). In particular, the invention relates to combinations of 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives which have been found to inhibit phosphodiesterase 2 (PDE2), with inhibitors of phosphodiesterase 10 (PDE10). Particular PDE10 inhibitors are selected from the group of MP-10, PQ-10, TP-10, papaverine, and the compounds disclosed in WO 2011/051324 and in WO 2011/110545. The invention is also directed to pharmaceutical compositions comprising such combinations, to processes for preparing such compositions, to the use of PDE2 inhibitors, in particular of 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives for the potentiation of said PDE10 inhibitors, and to the use of said PDE10 inhibitors for the potentiation of the effect of said PDE2 inhibitors, in particular, 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives, and to the use of such combinations and compositions for the prevention and treatment of disorders in which PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases.

SPLICE VARIANTS OF THE HUMAN 5-HT4 SEROTONINERGIC RECEPTOR AND THEIR APPLICATIONS, ESPECIALLY FOR SCREENING

NOVEL TRICYCLIC COMPOUNDS, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

NOVEL TRICYCLIC AMIDES, PROCESSES FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Electron accelerator, for non-destructive testing or irradiation of products or substances, has cavity excited so that it presents maximum electric field in direction of cavity axis and zero magnetic field

The accelerator has an electron source and a circular accelerator (S) which has a resonant cavity (1) formed by a tube (2). The cavity is excited in a mode that, in zones moving away from the axis, presents maximum electric field in the direction of the cavity axis (zz) and zero magnetic field. The electrons leave at one of these zones and are re-injected into another of these zones.

5-Aminoethylated derivatives of oxazolidin-2-one, process for their preparation and their application in therapeutics

Mixture of the 4 stereoisomers of formula I below, each of the corresponding racemic pairs of diastereoisomers and each of the enantiomers corresponding to each pair, that is to say each of the said stereoisomers: in which R1 represents: - a hydrogen atom, - an alkoxy group containing from 1 to 4 carbon atoms, - a trifluoromethyl group, or - one or two halogen atoms; and the pair R2, R3 takes one of the following meanings: (H, H), (H, C1-C4 alkyl), (C1-C4 alkyl, C1-C4 alkyl), and their addition salts with organic and inorganic acids.

5-HYDROXYETHYL DERIVATIVES OF OXAZOLIDINONE-2, PROCESSES FOR THEIR PREPARATION AND THERAPEUTIC APPLICATIONS

Multi-arm rear wheel axle unit comprises, for each wheel, rear and front transverse arms pivoted by elastic connections to chassis and to wheel pivot

The rear wheel axle unit comprises, for each wheel, a rear transverse arm (4) and a longitudinal arm pivoted by elastic connections to the vehicle chassis (8) by one of their ends and to the wheel pivot (10) at their opposite ends. A front transverse arm (2) is pivoted by an elastic connection to the chassis at one of its ends and to the wheel pivot at its other end by an elastic connection. A damper (12) comprising a rod is connected to the chassis by an elastic connection and a body integral with the wheel pivot pin. There is a helical suspension spring (13) which is not coaxial with the damper.

DEFORMABLE CROSS-REAR AXLE WITH SEPARATE SHOCK ABSORBER AND SPRING

Mechanical control means effecting a one-way linear displacement and follower means effecting a reciprocating displacement and motor vehicle rear steering control system

The present invention relates to a mechanical device with a control means effecting a one-way linear displacement and a follower means which as a consequence effects a reciprocating displacement. The device is characterised in that the control means (9) acts on the piston (6) of a hydraulic actuator (1) and the follower means (11) is actuated by a differential hydraulic actuator (2) hydraulically connected to the control hydraulic actuator (1) in closed circuit. The invention finds an application in particular for controlling the rear steering of a motor vehicle with four-wheel steering.

Vehicle roof has series of transverse rigid panels hinged by sections of a connecting membrane with shoes on the edges of alternate hinges that slide in guide rails at the sides of the roof

The vehicle roof is made from a series of transverse rigid panels (3) hinged by sections of a connecting membrane (4) with shoes on the edges of alternate hinges that slide in guide rails at the sides of the roof. The hinges allow the panels to adopt a more or less vertical position in a series of accordion pleats when the roof is open. The hinges are formed by a single membrane running through the middle of the panels.

1,8-Naphthalimide derivatives, process for their preparation and the pharmaceutical compositions containing them

The subject of the invention is new 1,8-naphthalimide derivatives of formula in which R, R1 and R2 each independently represent a hydrogen atom, a halogen atom, a nitro, nitroso, (C1-C4)alkyl, (C5-C6)cycloalkyl, phenyl, naphthyl, hydroxyl, (C1-C4)alkoxy, optionally substituted phenoxy, mercapto, (C1-C4)alkylthio, optionally substituted phenylthio, phenylmethylthio, (C1-C4)alkylsulphinyl, (C1-C4)alkylsulphonyl, optionally substituted phenylsulphonyl, phenylmethylsulphonyl, chlorosulphonyl, chloroformyl, chloromethyl, (C2-C3)alkanoyl, (C2-C3)alkanoyloxy, benzoyl or nitrobenzoyl group or an amino group of formula NR3R4 where R3 and R4 each independently represent a hydrogen atom, a (C1-C4)alkyl group or an optionally substituted phenyl group or R3 and R4, taken together with the nitrogen atom to which they are bonded, represent a piperidino, morpholino, piperazino or pyrrolidino group, and their addition salts with acids. Another subject of the invention is the process for their preparation and the pharmaceutical compositions containing them. The new compounds (I) show a particularly advantageous antagonist activity for 5-HT3 receptors.

NOVEL AMINOMETHYL-5-OXAZOLIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USE THEREOF

NOUVEAUX DERIVES AMINOMETHYL-5 OXAZOLIDINIQUES. CES DERIVES REPONDENT A LA FORMULE GENERALE: (CF DESSIN DANS BOPI) DANS LAQUELLE AR REPRESENTE UN GROUPE PHENYLE; PHENYLE SUBSTITUE PAR UN ATOME D'HALOGENE OU PAR UN GROUPE TRIFLUOROMETHYLE; OU LE GROUPE (CHLORO-3 FLUORO-4) PHENYLE, ET N EST SOIT EGAL A ZERO, SOIT EGAL A 1 AUQUEL CAS X EST UN ENCHAINEMENT CHOISI PARMI LES SUIVANTS: -CH-CH-, -CHCH-, -CC-, -CH-O- DONT LE GROUPE CH EST RELIE A AR. MEDICAMENT EN PARTICULIER POUR LE TRAITEMENT DES TROUBLES DU SYSTEME NERVEUX CENTRAL ET DE LA SENESCENCE. NEW AMINOMETHYL-5 OXAZOLIDINIC DERIVATIVES. THESE DERIVATIVES MEET THE GENERAL FORMULA: (CF DESSIN IN BOPI) IN WHICH AR REPRESENTS A PHENYL GROUP; PHENYL SUBSTITUTED BY A HALOGEN ATOM OR BY A TRIFLUOROMETHYL GROUP; OR THE GROUP (CHLORO-3 FLUORO-4) PHENYL, AND N IS EITHER EQUAL TO ZERO, OR EQUAL TO 1 IN WHICH CASE X IS A CHOSEN CHOSEN FROM THE FOLLOWING: -CH-CH-, -CHCH-, -CC-, -CH-O- WHOSE CH GROUP IS CONNECTED TO AR. MEDICINAL PRODUCT IN PARTICULAR FOR THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM AND OF SENESCENCE.

DEVICE FOR ORIENTATION OF A MOTOR VEHICLE SEAT

1-Heterocyclyl piperazine, homo:piperazine and piperidine derivs. - useful as antihypertensive agents

Heterocycles of formula (I) and their acid addition salts are new: In (I) X is N and n is 1 or 2 or X is VH and n is 1. R is H, 1-5C alkylcarbonyl or alkoxycarbonyl, heterocyclylcarbonyl (heterocyclyl is furyl, thienyl, tetrahydrofuryl, pyridyl or 2-methylthio 1,3,4-oxadiazol-5-yl) benzoyl, 3,4,5-trimethoxy cinnamoyl, allyloxycarbonyl, 2-methyl 1-propen-3-yloxycarbonyl, benzyloxycarbonyl or phenoxycarbonyl; R can also be phenylthio provided X is not CH; Ar is 4(7)-benzimidazolyl (opt. 2-substd. by 1-4C alkyl, phenyl or benzyl); 6-purinyl (provided X is not N and H), 4(7)-benzotriazolyl; 7-indolyl; or, when X is N and n is 1, 4-indolyl. (I) are useful as cardiovascular agents, particularly antihypertensives. Typical cpds. have intravenous LD50 in mice 125 mg per kg or more, and can be formulated for daily doses of up to 0.5g.

Electronic tube e.g. inductive output tube, control grid, has multiple primary bars, regularly spaced around central disc, including two concentric crowns fixed to disc, where one crown extends to develop circle around disc

The grid has multiple primary bars (41) that are regularly spaced around a central disc (9), where each bar includes two concentric crowns (43, 44) fixed to the central disc. The crown (43) extends to develop a circle around the central disc. Secondary bars (42) approximately concentric to the central disc are fixed to a periphery of the crowns (43), such that the crown (44) extend from the respective bars (42).

NOVEL TETRAZOLIC DERIVATIVES SUBSTITUTED IN POSITION 5, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC USE

NOUVEAUX DERIVES TETRAZOLIQUES REPONDANT A LA FORMULE: (CF DESSIN DANS BOPI) DANS LAQUELLE R REPRESENTE: -SOIT UN ATOME D'HYDROGENE, AUQUEL CAS R DESIGNE UN GROUPE ALKYLE RAMIFIE COMPORTANT AU MOINS CINQ ATOMES DE CARBONE OU UN GROUPE ALKENYLE RAMIFIE; -SOIT UN GROUPE METHYLE, AUQUEL CAS R REPRESENTE L'ENCHAINEMENT (PROPYL-1) N BUTYLE. CES NOUVEAUX DERIVES SONT UTILES EN TANT QUE MEDICAMENTS, NOTAMMENT POUR LEUR ACTION AU NIVEAU DU SYSTEME NERVEUX CENTRAL. NEW TETRAZOLIC DERIVATIVES RESPONDING TO THE FORMULA: (CF DRAWING IN BOPI) IN WHICH R REPRESENTS: EITHER ONE HYDROGEN ATOM, IN WHICH CASE R DESIGNATES A RAMIFIED ALKYL GROUP CONTAINING AT LEAST FIVE CARBON ATOMS OR AN ALKYL RAMP; - IS A METHYL GROUP, IN WHICH CASE R REPRESENTS THE (PROPYL-1) N BUTYL CHAIN. THESE NEW DERIVATIVES ARE USEFUL AS MEDICINES, IN PARTICULAR FOR THEIR ACTION AT THE LEVEL OF THE CENTRAL NERVOUS SYSTEM.

Vehicle steering device has a pivoting articulation connected with the pivoting part of another pivoting articulation, and including a pivoting part forming a support for a pivot on which a steering handle is rotatably mounted

The device comprises: a first pivoting articulation (4) comprising a first fixed part (12) connected to the structure of the vehicle, and a first pivoting part (30) pivoting around a first axis (x-x) and connected with the first fixed part; a second pivoting articulation (6) defining a second pivoting axis non-colinear with the first axis and connected with the first pivoting part, and comprising a second pivoting part (72) pivoting around the second axis and forming a support for a pivot (8); and a handle (10) for gripping by the driver and having a first end pivotally mounted on the pivot. An independent claim is also included for a vehicle comprising the above steering device and located on the left or the right of the driver's seat.

N-Aryl-azolidone cpds. - useful as psychotropic agents and antidepressants (NL 11.12.79)

Azolidone derivs. of formulae (Ia)-(Ie) and intermediates for their prepn. are claimed. In (Ia) (i) R2 is CH2OCOR3, where R3 is 1-8C alkyl, cyclohexyl, Ph, CH2OMe or CH2OPh, and R is a p-substituent comprising n-BuO, 3-methylbutoxy, cyclopentylmethoxy, cyclohexylmethoxy, 2-cyanoethoxy, OCH2CN or OCH2Ar, where Ar is Ph, m-chlorophenyl, m- or p-fluorophenyl, m-cyanophenyl, m-nitrophenyl, 3-nitro-5-chlorophenyl or 3-nitro-5cyanophenyl; or (ii) R2 is CH2OR6, where R6 is 1-5C alkyl, cycloexhyl, allyl, propargyl or CH2OMe, and R is m-Me or a p-substituent comprising 4-6C alkoxy, (4-7C cycloalkyl)methoxy, 1-methyl-1-cyclopentylmethoxy, 1-cyclopentenylmethoxy, 1-cyclohexenylmethoxy, 2-butenyloxy, 3-methyl-2-butenyloxy, 4-chlorobytoxy, 2-cyanoethoxy, 3-cyanopropoxy, 4-cyanobutoxy, 2-oxopropoxy, 4-oxo 1-cyclohexylmethoxy, 2-morpholinoethoxy, NEt2, 4- or 3-tetrahydropyranyloxy, trans-styryl (opt. m-substd. by Cl, CN or NO2), cis-styryl (opt. m-substd. by NO2), PhC=C, phenethyl, phenyl or OCH2AR', where Ar' is Ph, 3- or 4-Cl-phenyl, 3- or 4-F-phenyl, 3-I-phenyl, 3-Br-phenyl, 3-CF3-phenyl, 3- or 4-NO2-phenyl, 3- or 4-CN-phenyl, 3-Cl-4-F-phenyl, 3-CN,4-F-phenyl, 3-NO2-4-F-phenyl, 3,4-di-Cl-phenyl, 3-Cl-4-NO2-phenyl, 3-Cl-5-NO2-phenyl, 3-CN-5-NO2-phenyl or 3 5-di-Cl-phenyl; or (iii) CH2NR12R13. where NR12R13 is NH2, NHMe, NHEt, NHCHMe2, NME2, pyrrolidino or morpholino, and R is a p-substituent comprising n-BuO, 3-methylbutoxy, cyclopentylmethoxy, cyclopentylmethoxy, cyclohexylmethoxy, OCH2CN, OCH2CH2CN or OCH2Ar", where Ar" is Ph, 3-Cl-phenyl, 4-F-phenyl, 3-CN-phenyl, 3-NO2-phenyl or 3-Cl-5-NO2-phenyl). In (Ib)-(Ie) (i) R'2 is CH2OH and R' is 2-5C alkoxy, cyclopentylmethoxy, cyclohexylmethoxy, 1-cyclohexenylmethoxy, 4-tetrahydropyranylmethoxy, O(CH2)nCN(n=1-4) or OCH2Ar1, where Ar1 is 3- or 4-Cl-phenyl, 3- or 4-F-phenyl, 3-NO2-phenyl, 3-CN-phenyl, 3-CF3-phenyl, 3-Cl-5-NO2-phenyl or 3-CN-4-F-phenyl; or (ii) R'2 is CH2OR16, where R16 is 1-3C alkyl, and R ...

Vehicle wheel triangular suspension

The suspension (1) comprises two symmetrical arms (2) in the same plane connecting the wheel to the bodywork. Each arm has an internally projecting part (12) which enables it to be fixed to a deformable cross member (11). They are each fixed to this cross member by bolts passing through holes (13) in the corresponding arm. Each arm supports a wheel sub-assembly and is connected by an elastic articulation (4) to a vehicle cross member.

Multi-arm rear wheel axle unit comprises, for each wheel, rear and front transverse arms pivoted by elastic connections to chassis and to wheel pivot and omega shaped suspension spring

The rear wheel axle unit comprises, for each wheel, two front (2) and rear (4) transverse arms and a longitudinal arm pivoted by elastic connections to the vehicle chassis (8) at one of their ends and to the wheel pivot (10) at their opposite ends. There is an omega shaped suspension spring (13) and damper (12) which comprises a rod (12a)) connected to the chassis by an elastic connection and a body (12b) fixed to the wheel pivot.

OXAZOLIDINONE-2 5-HYDROXYETHYL DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS

MELANGE DES 4 STEREOISOMERES DE FORMULE I CI-DESSOUS, CHACUN DES COUPLES DE DIASTEREOISOMERES RACEMIQUES CORRESPONDANTS ET CHACUN DES ENANTIOMERES CORRESPONDANT A CHAQUE COUPLE : (CF DESSIN DANS BOPI) DANS LAQUELLE R REPRESENTE : - LE GROUPE BENZYLOXY; - LE GROUPE BENZYLOXY SUBSTITUE PAR UN OU DEUX ATOMES D'HALOGENE; PAR UN GROUPEMENT ALKOXY COMPORTANT DE 1 A 4 ATOMES DE CARBONE; OU PAR UN GROUPEMENT OU TRIFLUOROMETHYLE; - UN RADICAL HYDROXY; - UN GROUPE ALKOXY LINEAIRE OU RAMIFIE, COMPRENANT DE 1 A 6 ATOMES DE CARBONE; OU - UN GROUPE CYCLOALKYLALKYLOXY COMPRENANT DE 4 A 7 ATOMES DE CARBONE. CES COMPOSES TROUVENT LEUR APPLICATION EN TANT QUE MEDICAMENTS INHIBITEURS DE LA MONOAMINE OXYDASE, EN PARTICULIER DE LA MONOAMINE OXYDASE DE TYPE B.

NOVEL CYCLOALKYLENIC CHAIN CYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

L'invention concerne les composé de formule (I) : (CF DESSIN DANS BOPI) dans laquelle :. R représente un groupement ORa , SRa , Ra ou un groupement cyclique. A est une structure cyclique. G1 et G2 représentent une chaîne alkylène ou une liaison simple. B représente un groupement -NR1 a C (Q) R2 a' -NR1 a C(Q)NR2 a R1 a ou C (Q) NR1 a R2 a . p et q sont tels que 1 <= p + q <= 4 Médicaments. The invention relates to the compounds of formula (I): (CF DRAWING IN BOPI) in which :. R represents an ORa, SRa, Ra group or a cyclic group. A is a cyclic structure. G1 and G2 represent an alkylene chain or a single bond. B represents a group -NR1 a C (Q) R2 a '-NR1 a C (Q) NR2 a R1 a or C (Q) NR1 a R2 a. p and q are such that 1 <= p + q <= 4 Drugs.

Mechanical control means carrying out a linear unidirectional movement and follower means carrying out a reciprocating movement and rear direction control system of a motor vehicle.

REAR STEERING CONTROL DEVICE FOR FOUR STEERING WHEELS MOTOR VEHICLE

Use of 4-amino-5-chloro-2-methoxybenzoic esters as 5-ht4 agonists

Use of compounds of formula (I), wherein n is 1 or 2, R is a hydrogen or halogen atom or a cyano, hydroxy, (C1-C4)alkyl, (C1-C4)alkoxy, carboxy, (C1-C4)alkoxycarbonyl, aminocarbonyl, mono(C1-C4)alkylaminocarbonyl, di(C1-C4)alkylaminocarbonyl, mono(C1-C4)alkylamino, di(C1-C4)alkylamino, (C1-C5)alkanoylamino or (C1-C5)alkanoyl group; when R is a hydrogen atom the dotted line can denote a double bond. The invention also concerns the pharmaceutically acceptable salts and quaternary ammonium salts of said compounds which are useful for the preparation of drugs having a 5-HT4-agonist activity.

Cathode with rapid switching on and off of the heating and electronic grid tube comprising such a cathode.

Use of piperidinoethyl esters of 4-amino-5-chloro-2-methoxybenzoic acid as 5-HT4 agonists.

HUMAN 5-HT4 SEROTONINERGIC RECEPTOR SPLICE VARIANTS AND THEIR APPLICATIONS, IN PARTICULAR FOR SCREENING

The invention concerns an isolated polypeptide constitutive of splice variants for human serotonin receptor whereof the amino acid sequence is selected among the sequence SEQ ID N DEG 2 of the 5-HT4(c) polypeptide variant or the sequence SEQ ID N DEG 4 of the 5-HT4(d) polypeptide variant, or any polypeptide fragment or biologically active derivative thereof. The invention also concerns the inverse agonist effect of ML 10375 on 5-HT4(c) and 5-HT4(d) receptors.

Motor vehicle structure with at least one junction node of elongated elements, such as side members, uprights, cross members of the vehicle.

REAR AXLE WITH MULTI-ARM AXLE AND BLADE SPRING

ABSOLUTE CONFIGURATION ENANTIOMERS OF AMINO-3 QUINUCLIDINE AMIDE DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION

ENANTIOMERE DE CONFIGURATION ABSOLUE S DE FORMULE : (CF DESSIN DANS BOPI) OU X O OU S. AR REPRESENTE UN NOYAU PHENYLE SUBSTITUE PAR UN, DEUX OU TROIS GROUPES ALKOXY EN C-C; UN NOYAU PHENYLE SUBSTITUE EN POSITION 2 PAR UN GROUPE CH ET EN POSITION 5 PAR UN ATOME D'HALOGENE OU UN GROUPE ALKYLCARBONYLE INFERIEUR; UN NOYAU PHENYLE SUBSTITUE EN POSITION 2 PAR OCH, EN POSITION 4 PAR NH OU ALKYLCARBONYLE -NH- ET EN POSITION 5 PAR UN HALOGENE; UN GROUPE (FLUORO-3 METHOXY-2) PHENYLE; UN GROUPE PYRIMIDYNYLE-5 SUBSTITUE EN POSITION 2 PAR NH ET EN POSITION 4 PAR ALKOXY OU PHENYLOXY. CES COMPOSES SONT UTILES EN TANT QUE MEDICAMENTS A ACTIVITE GASTROCINETIQUE ET ANTIEMETIQUE. ENANTIOMER OF ABSOLUTE CONFIGURATION S OF FORMULA: (CF DRAWING IN BOPI) OR X O OR S. AR REPRESENTS A PHENYL CORE SUBSTITUTED BY ONE, TWO OR THREE ALKOXY GROUPS IN C-C; A PHENYL CORE SUBSTITUTED IN POSITION 2 BY A CH GROUP AND IN POSITION 5 BY A HALOGEN ATOM OR A LOWER ALKYLCARBONYL GROUP; A PHENYL CORE SUBSTITUTED IN POSITION 2 BY OCH, IN POSITION 4 BY NH OR ALKYLCARBONYL -NH- AND IN POSITION 5 BY A HALOGEN; A GROUP (FLUORO-3 METHOXY-2) PHENYL; A PYRIMIDYNYL-5 GROUP SUBSTITUTES IN POSITION 2 BY NH AND IN POSITION 4 BY ALKOXY OR PHENYLOXY. THESE COMPOUNDS ARE USEFUL AS MEDICINAL PRODUCTS WITH GASTROKINTIC AND ANTIEMETIC ACTIVITY.

SURFACE TREATMENT DEVICE

Cyano:pentyl:phenyl-methoxymethyl-oxazolidinone - useful as antidepressant

3-(4-(5-cyanopentyl)phenyl-5 -methoxymethyl-2 -oxazolidinone of formula (I) is new. The intermediates 3-(4-(5-benzyloxypentyl) phenyl-5 -methoxymethyl-2 -oxazolidinone (II) is also new. (I) is prepd. by treating 3-(4-(5-hydroxypentyl)phenyl-5 -methoxymethyl-2 -oxazolidinone (III) with mesyl chloride in a basic medium and reacting the prod. with an alkali metal cyanide. (I) is an antidepressant with ca. 300 times the reserpine-antagonist activity of toloxatone and with low toxicity (LD50 above 1000 mg/kg, p.o., mouse).

Friction hysteresis mechanism for automobile brake pedal control lever comprising sleeve articulated around spindle consists of friction plate coaxial with sleeve having fixed and movable cheek webs with interposed friction lining

La présente invention concerne un mécanisme d'hystérésis à friction (2) pour un levier de commande (1), notamment une pédale de frein d'un véhicule automobile, ledit levier (1) comportant un manchon (4; 17) articulé autour d'un axe fixe (3), caractérisé en ce qu'il est constitué d'un plateau de friction (7) monté coaxialement sur le manchon (4; 17) du levier de commande (1), ce plateau de friction (7) étant muni d'un flasque fixe (8), d'un flasque mobile (9; 9') et de moyens de friction (11; 27, 31), interposés entre lesdits flasques (8 et 9 ou 9'), qui sont mobiles en rotation autour du manchon (4; 17) par l'intermédiaire d'une roue libre (10) et en ce qu'un ressort de compression (12), monté coaxialement autour du manchon (4; 17), maintient une pression sur le flasque mobile (9; 9') en direction du flasque fixe (8).

Device for controlling rear steering for a motor vehicle with four-wheel steering

The present invention relates to a device for controlling rear steering. The device is characterised in that it comprises a plate forming a cam (41) and two rollers (46, 47) located in the same vertical midplane containing the longitudinal axis (Y-Y') of a rear steering rod (13) controlling the pivoting of rear wheels. The invention finds an application in motor vehicles with four-wheel steering.

OPTICALLY ACTIVE OXAZOLIDINONE-2 N-ARYLATED DERIVATIVES, SPECIFIC AND REVERSIBLE INHIBITORS OF MONOAMINE OXIDASE TYPE B AND PROCESS FOR PREPARING THE SAME

DERIVES DE L'OXAZOLIDINONE-2 N-ARYLEE REPONDANT A LA FORMULE: (CF DESSIN DANS BOPI) ET DE CONFIGURATION S (), A REPRESENTANT DANS CE CAS LE RADICAL HYDROXYLE OU DE CONFIGURATION R (), A DESIGNANT ALORS LE GROUPE N-METHYLAMINO, AINSI QUE LEURS SELS D'ADDITION D'ACIDE. APPLICATION EN THERAPEUTIQUE, NOTAMMENT EN TANT QU'INHIBITEURS DE LA MONOAMINE OXYDASE. DERIVATIVES OF OXAZOLIDINONE-2 N-ARYLEE RESPONDING TO THE FORMULA: (CF DRAWING IN BOPI) AND CONFIGURATION S (), A REPRESENTATING IN THIS CASE THE HYDROXYL RADICAL OR CONFIGURATION R (), THEN DESIGNING GROUP N- METHYLAMINO, AS WELL AS THEIR ACID ADDITIONAL SALTS. APPLICATION IN THERAPEUTICS, ESPECIALLY AS MONOAMINE OXIDASE INHIBITORS.

Device forming suspension for a motor vehicle rear wheel

The present invention relates to a device forming suspension for a rear wheel. The device is characterised in that it comprises an elastic means (5) located at the end of an arm (6) integral with the hub (3) of the wheel (R) and extending, from this hub, towards the front of the vehicle. The device finds an application especially in motor vehicles.

Storage device, for vehicles, is fitted to inside of roof of vehicle and is accessible from both inside and outside of vehicle

The roof of the vehicle is fitted with a storage container (2), which is fitted on the inside of the roof (1), and which is accessible from inside and outside the vehicle.

Device for controlling the steering of a motor vehicle rear axle assembly

The present invention relates to a device for controlling the rear steering. The device is characterised in that the rear wheel hub (15) is articulated to a suspension arm (14) about a substantially vertical axis (16) situated to the rear of the wheel axis (X-X') and in that it includes a control element (11) acting on the hub (15) in order to make it pivot about the vertical axis (16). The invention finds an application in motor vehicles with four wheel steering.

Multi-arm rear wheel axle unit comprises, for each wheel, rear and front transverse arms pivoted by elastic connections to chassis and to wheel pivot and helical suspension spring

The rear wheel axle unit comprises, for each wheel, two front and rear (4) transverse arms and a longitudinal arm pivoted by elastic connections to the vehicle chassis (6) at one of their ends and to the wheel pivot (8) at their opposite ends. There is a helical suspension spring (14) and a damper (12) which comprises a rod (12a)) connected to the chassis by an elastic connection and a body (12b) fixed to the wheel pivot.

NOVEL O-ARYLMETHYL N- (THIO) ACYL HYDROXYLAMINES, PROCESS FOR THEIR PREPARATION, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

HYDRAULIC SHOCK ABSORBER FOR FITTING A SUSPENSION MEMBER, FOR EXAMPLE OF A MOTOR VEHICLE

BIKE HOLDER FOR MOTOR VEHICLE

Bike rack for motor vehicle, has structure with two tubes, each provided with two arms at end of fixing unit on receiving tube, where arms are confined between tubes in arrangement position with saddle and handlebar supports

The rack has a structure with two tubes, each is provided with arms (4, 5) at an end of fixing unit on a receiving tube. Saddle support (11) and handlebar support (12) are maintained with respect to longitudinal axis of a vehicle. The tubes are connected to each other by the arms (4,5), each constituted of arms articulated around vertical axes. The arms (4,5) are confined between the tubes in arrangement position with the supports.

New arylalkyl (thio) amides, process for their preparation, and pharmaceutical compositions containing them.

Composés de formule (I): (CF DESSIN DANS BOPI) dans laquelle R1 , R2 , R3 , R4 , R5 et R6 sont tels que définis dans la description, leurs isomères optiques, et leurs sels d'addition à un acide ou à une base pharmaceutiquement acceptable lorsque R3 ou R4 représente un groupement salifiable. Médicaments. Compounds of formula (I): (CF DRAWING IN BOPI) in which R1, R2, R3, R4, R5 and R6 are as defined in the description, their optical isomers, and their addition salts with an acid or with a pharmaceutically acceptable base when R3 or R4 represents a salifiable group. Medications.

ENANTIOMERS OF ABSOLUTE CONFIGURATION OF AMINO-3 QUINUCLIDINE AMIDE DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION

REAR STEERING CONTROL DEVICE FOR A MOTOR VEHICLE WITH FOUR STEERING WHEELS.

MOTOR VEHICLE WHEEL SUSPENSION

Automobile steering wheel return mechanism comprises cam integral with wheel which engages support subjected to spring action exerting return couple on wheel and to damper exerting opposing couple

The return mechanism (15) for a steering wheel (10) comprises a cam (26) integral with the wheel which engages a support element (53). The support element is subjected to the action of a spring (46) which exerts a return couple on the wheel increasing over the initial range of the wheel displacement from a reference position. The support is also subjected to a damper (56) which exerts a couple opposing the displacement variation on the wheel.

Use of 4-amino-5-chloro-2-methoxy-benzoic acid piperidino-ethyl ester(s)

Use of 4-amino-5-chloro-2-methoxybenzoic acid piperidinoethyl esters of formula (I), and their salts and quaternary ammonium salts, as 5-HT4 agonists is new. R = H, halo, cyano, hydroxy, carboxy or aminocarbonyl, (1-4C) alkyl, alkoxy or alkoxycarbonyl, mono- or di- (1-4C) alkylaminocarbonyl, mono- or di- (1-4C) alkylamino, or (1-5C)alkanoylamino or alkanoyl.

Retractable vehicle seat, has retraction control device displacing seat towards floor of vehicle and moving seat longitudinally towards back of vehicle, where control device is connected to shock detection unit

The seat has a girdle type embarked belt (4) and a retraction control device disposed between a reinforcement (1) of a base (2) and a set of male (5) and female (6) slides. The control device connected to a shock detection unit displaces the seat towards a floor (7) of a vehicle and moves the seat longitudinally towards back of the vehicle. One of the pair of male and female slides is soldered to the floor.

EASY COUPLING RESONANT CAVITY

L'invention concerne une cavité (49) résonante à couplage facilité. Elle est délimitée par des parois (40, 42). Une (40) de ces parois comporte un orifice de couplage (41) pour coupler la cavité (49) à une autre cavité. La cavité (49) contient un mât (43) électroconducteur issu d'une second paroi (42) opposée à la première (40) et dressé face à l'orifice de couplage (41). Le mât (43) se termine par une partie (44) conformée en crochet en contact avec le bord de l'orifice de couplage. Applications notamment aux cavités secondaires de sortie de tubes à sortie inductive. The invention relates to an easily coupled resonant cavity (49). It is delimited by walls (40, 42). One (40) of these walls has a coupling port (41) for coupling the cavity (49) to another cavity. The cavity (49) contains an electrically conductive mast (43) issuing from a second wall (42) opposite the first (40) and facing the coupling orifice (41). The mast (43) ends with a part (44) shaped as a hook in contact with the edge of the coupling orifice. Applications in particular to secondary output cavities of inductive output tubes.

O-arylmethyl-n-acylhydroxylamine derivatives; pharmaceutical compositions

O-Aryl methyl N-acyl or N-thioacyl hydroxylamine derivs. of formula ArCH2ON(R1)C(=X)R2 (I), their enantiomers and diastereoisomers are new. X = O or S; R1 = H, alkyl, cycloalkyl, cycloalkylalkyl, aryl, or arylalkyl; R2 = R21 or R22; R21 = H or alkyl, alkenyl, alkynyl, cycloalkyl or cycloalkylalkyl all of which may be substd.; R22 = alkylamino, cycloalkylamino, or cycloalkylalkylamino which may be substd. on the (cyclo)alkyl gps.; Ar = naphthyl, indolyl, benzofuranyl, or benzothiophenyl, all of which may be partially or fully hydrogenated. alkyl, alkoxy = 1-6C, alkenyl, alkynyl = 2-6C, cycloalkyl = 3-8C, and opt. substits. on these may be halo, alkyl or alkoxy. Opt. substits. on Ar gps. are one or more gps. R; R = halo, OH, Ra, -CH2Ra, -O-Ra, -CO-Ra or -O-CO-Ra; Ra = opt. substd. alkyl, alkenyl, alkynyl, opt. substd. cycloalkyl, opt. substd. cycloalkylalkyl, opt. substd. aryl or opt. substd. aralkyl; the substits. on aryl and aralkyl gps. may be halo, alkyl, alkoxy, OH and/or haloalkyl.

Novel tricyclic compounds, preparation method and pharmaceutical compositions containing same

SUSPENSION FOR FRONT WHEEL OF MOTOR VEHICLE, WITH REDUCED FILTERING SYSTEM OF LONGITUDINAL SHOCK.

HORIZONTAL SUSPENSION FOR MOTOR VEHICLE WHEEL WITH LONGITUDINAL SHOCK FILTERING SYSTEM

Steering control device for a rear axle of a motor vehicle.

NOVEL CYCLOALKYLENIC CHAIN DERIVATIVES, THEIR PREPARATION PROCESS AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

RESONANT CAVITY WITH EASY COUPLING

L'invention concerne une cavité (49) résonante à couplage facilité. Elle est délimitée par des parois (40, 42). Une (40) de ces parois comporte un orifice de couplage (41) pour coupler la cavité (49) à une autre cavité. La cavité (49) contient un mât (43) électroconducteur issu d'une second paroi (42) opposée à la première (40) et dressé face à l'orifice de couplage (41). Le mât (43) se termine par une partie (44) conformée en crochet en contact avec le bord de l'orifice de couplage. Applications notamment aux cavités secondaires de sortie de tubes à sortie inductive. The invention relates to an easily coupled resonant cavity (49). It is delimited by walls (40, 42). One (40) of these walls has a coupling port (41) for coupling the cavity (49) to another cavity. The cavity (49) contains an electrically conductive mast (43) issuing from a second wall (42) opposite the first (40) and facing the coupling orifice (41). The mast (43) ends with a part (44) shaped as a hook in contact with the edge of the coupling orifice. Applications in particular to secondary output cavities of inductive output tubes.

5-(1-Propyl)n-butyl tetrazoles

New tetrazole derivatives, characterized in that they correspond to the formula: ##STR1## in which R 1 represents: either a hydrogen atom in any one of the positions 1 to 5 of the tetrazole nucleus, R designating a branched alkyl group comprising at least 5 carbon atoms or a branched alkenyl group, or a methyl group in position 2(3) of the tetrazole nucleus, R representing the (1-propyl)n butyl chain. These new derivatives are useful as medicaments, more especially for their anti-epileptic action.

RETURN DEVICE IN A STEERING WHEEL

Bicycle carrier for motor vehicle has longitudinal tubes with catches to fit onto mounting tubes attached to vehicle

L'invention a pour objet un porte-vélo comprenant une structure (10) de support d'au moins un vélo et destinée à être fixée à l'arrière d'un véhicule. La structure (10) est formée par un parallélogramme articulé et déformable en une position déployée de support dudit vélo et en une position repliée de rangement et comportant deux tubes (11; 12) longitudinaux et parallèles munis chacun à une extrémité d'un organe (21) de fixation sur un tube récepteur solidaire du châssis du véhicule, deux bras (13; 14) transversaux et parallèles et des moyens de maintien desdits vélos transversalement par rapport à l'axe longitudinal du véhicule automobile.

DERIVATIVES OF 5H-FURANONE-2 AND 3H-DIHYDROFURANONE-2, THEIR PREPARATION PROCEDURE AND THEIR THERAPEUTIC APPLICATION

N-ARIL-OXZOLIDINONES, -OXZOLIDINTIONS, -PYROLIDINONES, -PYROLIDINES AND -THIAZOLIDINONES, THEIR PREPARATION PROCEDURE AND THEIR APPLICATION IN THERAPY.

N-aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones are disclosed. These compounds possess antidepressant activity.

Cathode with fast heat switch-on and switch-off mechanism and grid-type electron tube including such a cathode

An electron tube cathode has a hollow cylindrical structure formed by thermo-emissive wires mounted between two conductive supports. The two supports are mechanically fixed to each other. To prevent the deformation of the cathode when the heating is turned on and turned off, at least one spring is used, this spring being integrated with one of the supports and being placed in the vicinity of the thermo-emissive wires. The spring is made of a material possessing elastic properties which, at ambient temperature, are lower than or equal to the properties that it has at a temperature greater than ambient temperature.

COMPACT ELECTRON ACCELERATOR WITH RESONANT CAVITY

New 1-acylaminomethyl-indan or -tetralin derivatives, are melatonin receptor ligands useful e.g. for treating sleeping disorders, anxiety, depression, jet lag or appetite disorders

1-Acylaminomethyl-4-alkyl-indan or 1-acylaminomethyl-5-alkyl-1,2,3,4-tetrahydronaphthalene derivatives (I) are new. Indane or tetralin derivatives of formula (I) and their enantiomers, diastereomers and acid or base addition salts are new. [Image] R 1>alkyl; R 2>alkyl (optionally substituted by one or more halo), 2-6C alkenyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl; n : 1 or 2; aryl moieties : phenyl, naphthyl or biphenylyl (all optionally substituted by 1-3 of alkyl, alkoxy, OH, COOH, CHO, CN, polyhaloalkyl, alkoxycarbonyl or halo); heteroaryl moieties : mono- or bicyclic aromatic group containing 1-3 of O, S and/or N as heteroatoms (optionally substituted as for aryl); and the alkyl moieties have 1-6C and cycloalkyl moieties 3-8C. An independent claim is included for the preparation of (I). ACTIVITY : Tranquilizer; hypnotic; antidepressant; cardiant; neuroleptic; CNS-Gen.; anorectic; eating disorders-Gen.; anticonvulsant; antidiabetic; antiparkinsonian; nootropic; antimigraine; neuroprotective; cerebroprotective; endocrine-Gen.; vasotropic; cytostatic; antifertility; contraceptive; immunomodulator; analgesic. MECHANISM OF ACTION : Melatonin receptor ligand. (I) have IC 50 values in receptor binding assays for one of the melatoninergic bonding sites (i.e. MT 1, MT 2 or MT 3 receptors); no specific values for individual compounds are given in the source material.

PROCEDURE FOR PREPARING DERIVATIVES OF 3H-DIHYDROFURANONE-2

Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl-[1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders

The present invention relates to combinations of phosphodiesterase 2 (PDE2) inhibitors with inhibitors of phosphodiesterase 10 (PDE 10). In particular, the invention relates to combinations of 1-aryl-4- methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives which have been found to inhibit phosphodiesterase 2 (PDE2), with inhibitors of phosphodiesterase 10 (PDE10). Particular PDE10 inhibitors are selected from the group of MP-10, PQ-10, TP-10, papaverine, and the compounds disclosed in WO 2011/051342 and in WO 2011/110545. The invention is also directed to pharmaceutical compositions comprising such combinations, to processes for preparing such compositions, to the use of PDE2 inhibitors, in particular of 1- aryl-4-methyl- [1,2,4]triazolo[4,3-a]-quinoxaline derivatives for the potentiation of said PDE10 inhibitors, and to the use of said PDE10 inhibitors for the potentiation of the effect of said PDE2 inhibitors, in particular, 1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]-quinoxaline derivatives, and to the use of such combinations and compositions for the prevention and treatment of disorders in which PDE2 and PDE10 are involved, such as neurological and psychiatric disorders, and endocrinological or metabolic diseases.

Automobile steering wheel return mechanism comprises first return spring exerting return couple on wheel and second spring comprising cam exerting second return couple on wheel

The return mechanism (15) for a steering wheel (10) comprises a first return spring (21) which exerts a first return couple on the wheel increasing over an initial range of the displacement from a reference position. A second return spring (30) comprising a cam (45) exerts a second return couple on the wheel having a maximum for a given displacement.

Suspension for a motor vehicle front wheel, with system for filtering out longitudinal impacts

The present invention relates to a suspension for a motor vehicle front wheel with a system for filtering out longitudinal impacts. This suspension which comprises a suspension link (30) articulated to the body of the vehicle so as to be able to travel in a plane approximately perpendicular to the attitude plane of the vehicle, a pendular element (35) articulated to the link via a transverse pin (35a), as well as a wheel support (50) secured to the pendular element, is characterised in that the so-called upper suspension link as well as a substantially parallel link termed lower link, are respectively articulated about a longitudinal axis, and the aforementioned transverse pin (35a) the rotational travel of which is limited by means forming a stop (80) is mounted on the link with the aid of two rolling-contact bearings (32a, 32b). This invention applies to the production of suspension for motor vehicles of all types.

5-AMINOETHYL DERIVATIVES OF OXAZOLIDINONE-2, THEIR PREPARATION PROCESS AND THEIR THERAPEUTIC APPLICATION

Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them

L'invention concerne les composés de formule (I) : R-A-R' (I) dans laquelle : .cndot. A est tel que défini dans la description .cndot. R représente un groupement (voir formule), ou -NR'a R"a où R'a et R" a sont tels que définis dans la description, .cndot. R' représente un groupement -(CH2)T-R2 dans lequel t et R2 sont tels que définis dans la description. Les composés de la présente invention présentent des caractéristiques pharmacologiques très intéressantes concernant les récepteurs mélatoninergiques et peuvent être utilisés pour le traitement de pathologies liées au système mélatoninergique.

Patent DE2157694B2

Piperidin-4-yl-pyridazin-3-ylamine derivatives as fast dissociating dopamine 2 receptor antagonists

The present invention relates to compounds that are fast dissociating dopamine 2 receptor antagonists, processes for preparing these compounds, pharmaceutical compositions comprising these compounds as an active ingredient. The compounds find utility as medicines for treating or preventing central nervous system disorders, for example schizophrenia, by exerting an antipsychotic effect without motor side effects.

N-Aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones

N-aryl oxazolidinones, oxazolidinethiones, pyrrolidinones, pyrrolidines and thiazolidinones are disclosed. These compounds possess antidepressant activity.

Splice variants for human 5-HT4 serotonin receptor and their applications, in particular for screening

The invention concerns an isolated polypeptide constitutive of splice variants for human serotonin receptor whereof the amino acid sequence is selected among the sequence SEQ ID No. 2 of the 5-HT 4(c) polypeptide variant or the sequence SEQ ID No. 4 of the 5-HT 4(d) polypeptide variant, or any polypeptide fragment or biologically active derivative thereof. The invention also concerns the inverse agonist effect of ML 10375 on 5-HT4(c) and 5-HT4(d) receptors.

REAR STEERING CONTROL DEVICE FOR FOUR-WHEEL MOTOR VEHICLE

La présente invention concerne un dispositif de commande de direction arrière d'un véhicule automobile. Le dispositif est caractérisé en ce que le doigt 36 portant la partie formant galet 37, 38 est solidaire d'un moyeu 35 fixé rigidement coaxialement aux deux extrémités adjacentes respectivement des deux barres des directions arrière 13 et l'arbre d'entraînement 10 est accouplé à un disque 22 à denture périphérique pour l'entraîner en rotation autour de son axe lors du braquage des roues avant de façon que la rainure formant came 39 provoque le déplacement des barres de direction arrière 13 parallèlement à l'axe X-X'. La présente invention trouve application dans le domaine de l'automobile. The present invention relates to a device for controlling the rear direction of a motor vehicle. The device is characterized in that the finger 36 carrying the part forming a roller 37, 38 is integral with a hub 35 rigidly fixed coaxially to the two adjacent ends respectively of the two bars of the rear directions 13 and the drive shaft 10 is coupled. to a disc 22 with peripheral toothing to drive it in rotation about its axis during the deflection of the front wheels so that the cam-forming groove 39 causes the displacement of the rear steering bars 13 parallel to the axis X-X '. The present invention finds application in the automotive field.

N 4-Hydroxy or benzyloxy-phenyl 2-oxazolidinone and pyrrolidinone(s) - substd. by hydroxymethyl (derivs.) are intermediates for antidepressants

3-(4-W-O-phenyl)-5-B- 2-oxazolidinone and 1-(4-W-O-phenyl)-4-B-2 pyrrolidinone dervis. of formula (I') are new (where W is H or benzyl and (a) Z is O; B is -CH2-OR' and R' is opt. branched 1-3C alkyl, cyclohexyl or methoxymethyl or (b) Z is -CH2 and B is hydroxymethyl or when W is benzyl may also be ethoxycarbonyl or carboxy). (I') are intermediates for psychotropics and antidepressants of formula (I) (where (a) X, A, R, is O, O, H; R2 is -CH2-OR5; R5 is opt. branched 1-3C alkyl or cyclohexyl and R is para position is cyanobutoxy, n-butyloxy, 3-methylbutyloxy, cyclopentylmethoxy, cyclohexylmethoxy, cyclohex-1-eneyl-methoxy, cyanoethoxy, 3-cyanopropyloxy or R6-substd.-benzyloxy and R6 is H, 3-chloro, 4-chloro, 3-fluoro, 4-fluoro, 3-cyano, 3-trifluoromethyl or 3 nitro; or R5 is ally, propargyl or methoxymethyl and R in para position is metanitrobenzyloxy; or (b) X, A, R1 is O, -CH2, H; R2 is hydroxymethyl and R is para-(metanitrobenzyloxy). Activity tests are described which show cpds. (I) to be more active than Toloxatone. (I) may be administered orally (50-500mg/day) or parenterally (5-50mg/day).

Horizontal suspension unit for vehicle wheels

The unit consists of a suspension element (1), which is linked to the chassis of the vehicle. A pendular element (4) is fitted between the wheel (R) and the suspension element and consists of a primary part (4b), on which is mounted the axis (9) of the wheel, and a secondary part (4a), on which is mounted the suspension element, in such a way that the suspension element is only able to pivot, relative to the pendular element in one plane (V). An elastic stop (19) is interposed between the two elements, in order to limit the movement of the pendular element, around its link axis (15), which is transverse to the central plane of the vehicle. The elastic stop is located between at least one extension (20) of the secondary part of the pendular element and an internal wall (21) of the suspension element.

FORCE RETURN DEVICE FOR A BRAKE SYSTEM FOR A MOTOR VEHICLE OF THE ELECTRONICALLY CONTROLLED BRAKE TYPE

Isoxazoline derivatives functioning as antidepressants

The invention concerns substituted isoxazolines derivatives according to Formula (I): wherein X = CH<2#191, N-R>7<, S or O, R>1<, R>2< and R>3< are certain specific substituents, Pir is an optionally substituted piperidyl or piperazyl radical and R3 represents an optionally substituted aromatic homocyclic or heterocyclic ring system including a partially or completely hydrogenated hydrocarbon chain of maximum 6 atoms long with which the ring system is attached to the Pir radical and which may contain one or more heteroatoms selected from the group of O, N and S ; a process for their preparation, pharmaceutical compositions comprising them and their use as a medicine, in particular for the treatment of depression and/of anxiety and disorders of body weight. The compounds according to the invention have surprisingly been shown to have a serotonine (5-HT) reuptake inhibitor activity in combination with additional α2-adrenoceptor antagonist activity and show a strong anti-depressant activity without being sedative. Compounds according to the invention are also suitable for treating patients with anxiety disorders and disorders of body weight. The invention also relates to novel combination of substituted isoxazolines derivatives having anti-depressant activity and/or anxiolytic activity and/or body weight control activity with antidepressants, anxiolytics and/or antipsychotics to improve efficacy and/or onset of action.

5-Aminomethyl-2-oxazolidinone derivatives, their preparation and their therapeutical use

Mixture of the 4 stereoisomers of formula (I) below, each of the pairs of corresponding racemic diastereoisomers and each of the enantiomers corresponding to each pair, that is to say each of the said stereoisomers: …<IMAGE>… in which R1 denotes:… - a hydrogen atom,… - an alkoxy group containing from 1 to 4 carbon atoms,… - a trifluoromethyl group, or… - one or two halogen atoms;… and the pair (R2, R3) assumes one of the following meanings:… (H, H) (H, C1-C4 alkyl), (C1-C4 alkyl, C1-C4 alkyl), and their addition salts with an organic and inorganic acid. …<??>The compounds of formula (I) can be used in therapeutics.

5-aminoethyloxazolidin-2-one derivatives

A mixture of the 4 stereoisomers of formula (I) below, each of the pairs of corresponding racemic diastereoisomers and each of the enantiomers corresponding to each pair, that is to say each of said stereoisomers: ##STR1## in which R 1 represents: a hydrogen atom, an alkoxy group comprising from 1 to 4 carbon atoms, a trifluoromethyl group, or one or two halogen atoms; and the pair (R 2 , R 3 ) has one of the following meanings: (H, H), (H, C 1 -C 4 alkyl), (C 1 -C 4 alkyl, C 1 -C 4 alkyl), as well as their organic and inorganic acid addition salts. The compounds of formula (I) are therapeutically useful.

-N-substituted phenyl-5-methoxymethyl-2-oxazolidinones and pharmaceutical compositions containing same

A compound of the formula ##STR1## where R is selected from the group consisting of CH 3 --CO--(CH 2 ) 2 --O--, ##STR2## The compounds are useful in treating depression.

PROCEDURE FOR THE PREPARATION OF PARA-KINONIC OR ORTHO-KINONE DERIVATIVES, POSSIBLY ALCOXYLATED OR ARYLOXYLATED, RESPECTIVELY STARTING FROM THE CORRESPONDING HYDROKINONIC OR PYROCATECHIC DERIVATIVES

5-AMINOMETHYL-2-OXAZOLIDINONE DERIVATIVES, THEIR PRODUCTION AND THEIR USE IN THE MEDICINE.

TV/ radio electronic tube cooling unit having first hydraulic tube circulating fluid and fluid/fluid exchange transferring heat second hydraulic circuit/tube carrier mounted.

The cooling mechanism has an electronic tube (100) placed on a carrier (101) and has a first hydraulic circuit (103) with fluid circulating, cooling the tube. There is a fluid to fluid exchange (104) transferring heat to a second hydraulic circuit (120) which is on the tube carrier.

Derivatives of 1-[3-(4-hydroxyphenyl) 1-hydroxy 1-propyl] benzene substituted in position 2 by an aminoalkyleneoxy chain, the method of preparing same and the application thereof to therapeutics

The present invention relates to compounds of formula: ##STR1## in which: R 3 is hydrogen, 2-tetrahydropyranyl or benzyl; R 1 and R 2 are such that: either R 1 represents a methoxy group in which case R 2 is a group chosen from the following: hydroxyl; C 1 -C 4 alkyl; C 2 -C 8 alkyloxy; C 5 -C 7 cycloalkloxy; benzyloxy; or R 2 represents a methoxy group in which case R 1 is a group chosen from the following: hydroxyl; C 2 -C 8 alkyloxy; C 2 -C 8 alkyloxy substituted by a methoxy group; C 1 -C 4 trifluoroalkyloxy; C 3 -C 4 alkenyloxy; C 5 -C 7 cycloalkyloxy; benzyloxy; C 1 -C 4 alkylthio; n=2 or 3; and p=4, 5 or 6, as well as their addition salts with mineral or organic acids, said compounds and salts being useful as drugs.

Substituted cyclic compounds, a process for their preparation and pharmaceutical compositions containing the same

Patente de Invenção: <B>"COMPOSTOS CìCLICOS SUBSTITUìDOS, UM PROCESSO PARA SUA PREPARAçãO E COMPOSIçõES FARMACêUTICAS QUE CONTêM OS MESMOS"<D>. A invenção refere-se a compostos da fórmula (I): R-A-R' em que: A é como definido na descrição; R representa um grupo (V) -NR'~ a~R"~ a~ ou R'~ a~ e R"~ a~ em que R'~ a~ e R"~ a~ são como definidos na descrição, ou R forma com A uma estrutura cíclica como definido na descrição; R' representa um grupo (CH~ 2~)~ t~-R² em que q, t e R² são como definidos na descrição. A invenção é útil para a preparação de medicamentos.

Spurious wave attenuation device for electronic tube and electron tube comprising this device.

La présente invention concerne un dispositif d'atténuation d'ondes parasites apparaissant dans un tube électronique comportant au moins deux électrodes (2, 3) cylindriques coaxiales. Les électrodes (2, 3) contribuent à former les parois d'un résonateur coaxial. Les ondes parasites à atténuer génèrent des courants de surface dans les parois du résonateur coaxial. Le dispositif d'atténuation comporte plusieurs éléments résistifs (10) conducteurs de l'électricité insérés dans au moins une paroi du résonateur et disposés de manière à couper les courants de surface. Application: Tubes électroniques à grille. The present invention relates to a device for attenuating parasitic waves appearing in an electron tube comprising at least two coaxial cylindrical electrodes (2, 3). The electrodes (2, 3) help to form the walls of a coaxial resonator. The parasitic waves to be attenuated generate surface currents in the walls of the coaxial resonator. The attenuation device comprises several electrically conductive resistive elements (10) inserted into at least one wall of the resonator and arranged so as to cut off surface currents. Application: Grid electron tubes.

Rear axle for car comprises support with its lower part attached to rear end of arm, median part attached to wheel, and upper part attached to suspension rod

Left rear axle comprises deformable crosspiece (1), arm (2) attached to crosspiece, and suspension rod (3). Rear end (21) of arm is attached to lower part (51) of support (5). Support carries wheel (4) (left wheel) in its median part (52), and suspension rod in its upper part (53).